First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.
Bladder Cancer
BIOLOGICAL: Mycobacterial Cell-Wall DNA Complex|BIOLOGICAL: Bacillus Calmette-Guerin
Duration of disease-free survival (time to recurrence, progression or death) in all patients, Baseline, Month 3, 6, 9, 12, 15, 18, 21, and 24|Percent of patients who due to study drug-related AEs experience 2 consecutive treatment delays or discontinue due to drug related AEs, Baseline through 24 months
Disease-free survival rate at 2 years, Month 24|Frequency, severity, and nature of drug-related AEs, Baseline through 24 Months|Duration of progression-free survival (time to progression or death) in all patients, Baseline, Month 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48 and 60|Frequency, severity, and nature of drug-related SAEs, Baseline through 24 months|Number of treatment delays and their reason, Baseline, Month 3, 6, 9, 12, 15, 18, 21, and 24|Frequency, severity and nature of all AEs, Baseline through 24 months|Number of treatment discontinuations and their reason, Baseline through 24 months|Duration of Survival (time to death from any cause) in all patients, Baseline through month 60
The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.